Navigation Links
ACRYSOF® Natural IOL

ProductsACRYSOF® Natural IOL
Company Alcon Laboratories
Item ACRYSOF® Natural IOL
Features 
  • Highly cross-linked acrylate/methacrylate copolymer.
  • Foldability and strength and high refractive index.
  • Good biocompatibility, physical and chemical stability.
  • Covalently-bound UV absorber (benzotriazole).
  • Covalently-bound Blue Light-Filtering Chromophore.
Description Alcon introduces an intraocular lens that doesn't stop at UV filtration. Similar to the natural human lens, the new ACRYSOF® Natural IOL filters both UV and high-energy blue light. But while it filters blue light, it won't spoil your patient's view. That's just as clear and as beautiful as ever.
Info Alcon Laboratories
Customer Service: (800) 757-9195
Web site: http://www.alconlabs.com/

Related medicine products :

1. ACRYSOF® Multipiece Foldable IOL
2. The Natural Selection
3. Natural Selection
4. Natural-Knee
5. The Natural-Knee
6. The Comprehensive Natural-Knee Cruciate Retaining System
7. The Comprehensive Natural-Knee Posterior Stabilized System
8. Natural-Knee Revision system
9. The Natural-Knee Unicompartmental System
10. The Natural-Hip Family - Revision/Trauma Nonporous CoCr
11. The Natural-Hip Family - Revision/Trauma CoCr Revision
Other Medicine News:Health News:Contamination from depleted uranium found in urine 20 years later 2Health News:Red Cross Receives $250,000 From Wal-Mart to Assist With Southern California Wildfire Relief Efforts 2Health News:Red Cross Receives $250,000 From Wal-Mart to Assist With Southern California Wildfire Relief Efforts 3Health News:Marital Stress Linked to Heart Disease 2Health News:Marital Stress Linked to Heart Disease 3Health News:Young Innovations, Inc. Announces Results for the Third Quarter Ended September 30, 2007 and Declares Quarterly Dividend 2Health News:Young Innovations, Inc. Announces Results for the Third Quarter Ended September 30, 2007 and Declares Quarterly Dividend 3Health News:Young Innovations, Inc. Announces Results for the Third Quarter Ended September 30, 2007 and Declares Quarterly Dividend 4Health News:Young Innovations, Inc. Announces Results for the Third Quarter Ended September 30, 2007 and Declares Quarterly Dividend 5Health News:Young Innovations, Inc. Announces Results for the Third Quarter Ended September 30, 2007 and Declares Quarterly Dividend 6Health News:Susan G. Komen For The Cure, Karmanos Cancer Institute, Local Hospitals Call on Policymakers to Address Injustice and Unfairness in Breast Cancer Incidence and Mortality 2Health News:Susan G. Komen For The Cure, Karmanos Cancer Institute, Local Hospitals Call on Policymakers to Address Injustice and Unfairness in Breast Cancer Incidence and Mortality 3Health News:Susan G. Komen For The Cure, Karmanos Cancer Institute, Local Hospitals Call on Policymakers to Address Injustice and Unfairness in Breast Cancer Incidence and Mortality 4
Breaking Medicine Technology:Ambit Biosciences Corporation Presents Phase I Clinical Results of AC220 in Patients With Acute Myeloid Leukemia at ASH Conference 2Ambit Biosciences Corporation Presents Phase I Clinical Results of AC220 in Patients With Acute Myeloid Leukemia at ASH Conference 3Ambit Biosciences Corporation Presents Phase I Clinical Results of AC220 in Patients With Acute Myeloid Leukemia at ASH Conference 4FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 2FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 3Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 2Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 3Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 4Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 5Genomes of biofuel yeasts reveal clues that could boost fuel ethanol production worldwide 14759 1Genomes of biofuel yeasts reveal clues that could boost fuel ethanol production worldwide 14759 2Catholics for Choice Statement on Healthcare Reform Bill 60931 1Catholics for Choice Statement on Healthcare Reform Bill 60931 2Findings show nanomedicine promising for treating spinal cord injuries 10653 1Findings show nanomedicine promising for treating spinal cord injuries 10653 2Findings show nanomedicine promising for treating spinal cord injuries 10653 3